Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating
Geron Analyst Ratings
Buy Rating Affirmed for Geron Amid Positive Imetelstat Launch Prospects and Strong Financials
Analysts Conflicted on These Healthcare Names: Dyne Therapeutics (DYN) and Geron (GERN)
Geron Analyst Ratings
Geron Analyst Ratings
Buy Rating Affirmed for Geron Following Insightful Leadership Discussion and Promising Drug Development Progress
Analysts Offer Insights on Healthcare Companies: Carl Zeiss Meditec (GB:0DHC), Geron (GERN) and Zur Rose Group AG (Six Swiss: CH:DOCM)
Geron Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)
Geron Analyst Ratings
Stifel Nicolaus Reaffirms Their Buy Rating on Geron (GERN)
Geron Analyst Ratings
Geron Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), ACELYRIN, INC. (SLRN) and Geron (GERN)
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and MoonLake Immunotherapeutics (MLTX)
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Geron (GERN)
Geron Analyst Ratings
Stifel Nicolaus Sticks to Its Buy Rating for Geron (GERN)
Buy Rating on Geron Corp. Anchored by Imetelstat's FDA Approval Outlook and Favorable Safety Profile
No Data